Close Menu

NEW YORK (GenomeWeb) - Veracyte announced after the close of the market Thursday that revenues for its second quarter rose 37 percent year over year on sales of its Afirma gene expression classifier (GEC) tests.

For the three months ended June 30, 2015, the South San Francisco, California-based molecular diagnostics company said that revenues increased 37 percent to $11.9 million from $8.7 million a year ago, missing the average Wall Street expectation of $12.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.